What Is Ipamorelin? Selective GH Secretagogue Research
Ipamorelin is studied as one of the most selective GH secretagogues known — a ghrelin-receptor agonist that triggers GH release with a notably clean off-target profile in research models.
If you've searched "what is ipamorelin," the short answer is: a pentapeptide growth-hormone secretagogue that acts at the ghrelin receptor. What makes ipamorelin notable in the research literature is its selectivity — it is characterized as one of the cleanest GHS-R1a agonists available as a research tool, releasing growth hormone with little of the off-target hormonal noise seen with earlier secretagogues. This is a research-use-only overview of what it is and how it is studied.
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (five amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH2) classified as a growth-hormone secretagogue (GHS). Unlike a GHRH analog, which works through the GHRH receptor, ipamorelin works through the growth-hormone secretagogue receptor type 1a (GHS-R1a) — the same receptor the natural hormone ghrelin binds. Activating GHS-R1a prompts pituitary somatotrophs to release stored growth hormone. It belongs to the same broad class as earlier secretagogues such as GHRP-6 and GHRP-2, but was developed to be more selective than either.
How ipamorelin works at the receptor
When ipamorelin binds GHS-R1a, the receptor signals through the phospholipase-C pathway, raising intracellular calcium in the somatotroph and triggering GH release. There is a second mechanism researchers attribute to this class: partial suppression of somatostatin tone. Somatostatin is the brake on GH secretion, so reducing its influence amplifies release further. Together, the calcium-driven trigger and the somatostatin offset are what make a ghrelin-receptor agonist a potent releaser in model systems.
GHS-R1a is also notable for a high level of constitutive (ligand-independent) activity, meaning the receptor signals to some degree even without an agonist present. That baseline activity is part of why this receptor system is studied closely, and why a selective agonist like ipamorelin is useful for cleanly characterizing the agonist-driven component of the signal on top of that baseline.
Why "selective" matters
Many ghrelin-receptor agonists also nudge cortisol, prolactin, and ACTH — the stress and lactation hormones — which complicates interpreting any GH result. Ipamorelin is repeatedly described in the literature as releasing GH with minimal effect on those other hormones in the models studied. That selectivity is what makes it valuable as a research tool: a clean GHS-R1a signal with fewer confounding variables, so changes in GH can be attributed to the receptor of interest rather than a broad endocrine disturbance.
Ipamorelin vs a GHRH analog
Ipamorelin and a GHRH analog such as CJC-1295 are not interchangeable — they hit different receptors. Ghrelin-pathway (ipamorelin) and GHRH-pathway (CJC-1295) signaling are complementary, which is exactly why the two are studied together in the CJC-1295 + ipamorelin stack. Ipamorelin amplifies and triggers release; the GHRH analog raises baseline somatotroph readiness and enlarges the releasable pool. For how ipamorelin compares to other GHRH-side tools, see Sermorelin vs CJC-1295.
How ipamorelin is characterized in research models
- Receptor target: GHS-R1a (the ghrelin receptor)
- Class: pentapeptide growth-hormone secretagogue
- Signaling: phospholipase-C / intracellular calcium, plus partial somatostatin suppression
- Selectivity: minimal cortisol / prolactin / ACTH effect in reported models
- Signal: GH release studied as pulse-like rather than tonic
- Common pairing: alongside a GHRH analog to engage both pathways at once
Ipamorelin vs other secretagogues
Ipamorelin is often compared with the earlier GHRP-class secretagogues — GHRP-2 and GHRP-6 — that also act at GHS-R1a. The distinction researchers draw is selectivity. GHRP-6 is known for a strong appetite-stimulating effect and notable cortisol and prolactin activity; GHRP-2 is a potent releaser but likewise less selective. Ipamorelin was developed to retain the GH-releasing potency of that class while shedding most of the off-target endocrine activity. In a study where the goal is to attribute a GH change cleanly to ghrelin-receptor activation, that narrower profile is the reason ipamorelin is frequently the secretagogue of choice.
Quality and handling
Ipamorelin is supplied lyophilized and reconstituted with bacteriostatic water before in-vitro use; the reconstitution calculator returns the concentration and aliquot volume for any vial size so solutions can be prepared consistently across an experiment. Every ipamorelin lot from Eon Research ships lyophilized in multi-vial research kits from our US facility within 48 hours with tracking.
Frequently asked questions
What is ipamorelin?
A synthetic pentapeptide growth-hormone secretagogue that acts at the ghrelin receptor (GHS-R1a) to prompt pituitary GH release. It is studied as one of the most selective GHS-R1a agonists and is supplied research-use-only for in-vitro laboratory work.
What receptor does ipamorelin act on?
The growth-hormone secretagogue receptor type 1a (GHS-R1a), the same receptor the endogenous hormone ghrelin binds — distinct from the GHRH receptor that GHRH analogs like CJC-1295 target. It signals through phospholipase C and intracellular calcium.
Why is ipamorelin called selective?
Because in research models it stimulates GH release with minimal effect on cortisol, prolactin, and ACTH, giving a cleaner GHS-R1a signal with fewer confounding variables than less-selective secretagogues such as GHRP-6 or GHRP-2.